Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 04, 2022

Venetoclax and Azacitidine in Treatment-Naive Patients With AML and IDH1/2 mutations

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 mutations
Clin. Cancer Res 2022 Jan 19;[EPub Ahead of Print], DA Pollyea, CD DiNardo, ML Arellano, A Pigneux, W Fiedler, M Konopleva, DA Rizzieri, BD Smith, A Shinagawa, RM Lemoli, M Dail, Y Duan, B Chyla, J Potluri, CL Miller, HM Kantarjian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading